While the anti-VEGF technology is currently still a pre-clinical program, the same technology has been utilized in a Phase I clinical trial for the delivery of tyrosine kinase inhibitors in patients with n-AMD (ClinicalTrial.gov ID: NCT03630315). The gene discussed is VEGFA; the disease is age-related macular degeneration.